Naltrexone Interactions With Opioids, Alcohol, and Drugs

Naltrexone’s most consequential interaction is with opioids, where it can trigger severe precipitated withdrawal or, conversely, block the pain relief people need after surgery or injury. But the interaction profile of this medication extends well beyond opioids. Naltrexone influences stress hormones, may alter the effects of certain antidepressants, and behaves differently depending on the dose, the formulation, and even the patient’s genetics. Whether you take naltrexone for alcohol use disorder, opioid dependence, or an off-label condition, understanding how it interacts with other substances and body systems is more nuanced than the standard warning label suggests.

How Naltrexone Works and Why It Clashes With Opioids

Naltrexone is an opioid antagonist, meaning it binds to the same receptors that opioids use but does not activate them. It has a strong preference for the mu-opioid receptor, the primary target of drugs like morphine, heroin, and oxycodone, though it also blocks kappa and delta opioid receptors to varying degrees.¹ By occupying these receptors without producing any high, naltrexone effectively locks the door. If someone takes an opioid while naltrexone is on board, the opioid has nowhere to bind, and the person feels little to no effect from it.

This blocking action is the entire therapeutic point for people recovering from opioid addiction: it removes the reward. But it also creates the drug’s most dangerous interaction. If someone who is physically dependent on opioids takes naltrexone, the medication rapidly displaces opioids from their receptors, slamming the body into withdrawal within minutes rather than the gradual onset that occurs naturally. This precipitated withdrawal is far more intense and sudden than ordinary withdrawal, and it can be genuinely dangerous.

Precipitated Withdrawal With Opioids

Precipitated opioid withdrawal is the interaction that emergency departments deal with most acutely. In a study of 132 patients hospitalized after naltrexone-induced withdrawal, agitation was the most prominent symptom, occurring in about 96% of cases. Other common symptoms included altered consciousness (roughly 39%), nausea and vomiting (around 28% and 27% respectively), abdominal pain (about 24%), diarrhea, muscle and bone pain, rapid heart rate, and dilated pupils.² The agitation was consistently the hardest symptom to manage clinically.

This interaction is not limited to people who are actively using illicit opioids. It can also happen in patients on extended-release naltrexone (the injectable form, sold as Vivitrol) who use opioids late in a dosing cycle. One case report described a teenager receiving monthly Vivitrol injections who used oxycodone several days before her next scheduled dose, when naltrexone levels were dropping. She experienced mild intoxication from the oxycodone, suggesting partial breakthrough of the blockade, but then went into precipitated withdrawal as naltrexone levels fluctuated.³ The takeaway is that even with depot naltrexone, the blockade is not perfectly uniform over time, and any opioid use near the end of a dosing interval carries risk.

Because naltrexone is long-acting compared to the short-acting antagonist naloxone (Narcan), precipitated withdrawal from naltrexone tends to last longer and be harder to reverse in the emergency department.⁴ With naloxone, withdrawal symptoms typically resolve within 30 to 90 minutes. With naltrexone, the episode can stretch for hours, and there is no simple antidote because you cannot easily overpower naltrexone’s receptor binding with more opioids without risking respiratory depression once the naltrexone eventually clears.

Naltrexone and Pain Management Around Surgery

If you take naltrexone and need surgery, you and your surgical team face a real problem: the medication blocks the very drugs most commonly used for post-operative pain. Multiple studies have confirmed that patients on naltrexone require significantly more opioid medication to achieve pain relief after surgery, and even then, the blockade may not be fully overcome.⁵

Current clinical guidelines universally recommend stopping naltrexone before elective surgery, though the evidence base behind these recommendations is thin. A scoping review found that every published guideline document recommended preoperative cessation regardless of dose, indication, or route of administration, but none of these guidelines were built on systematic literature reviews or formal expert consensus protocols.⁶ For oral naltrexone, stopping the medication about 72 hours before a planned procedure is a common recommendation. For the injectable form, the timeline is more complicated because drug levels taper slowly over weeks.

When opioids are not an option or are insufficient, clinicians often turn to multimodal approaches. Ketamine, local anesthetics like lidocaine and bupivacaine, the antidepressant duloxetine, and non-drug methods like nerve blocks have all been used to manage pain in patients who cannot discontinue naltrexone or who are having emergency surgery.⁷ If you are on naltrexone, wearing a medical alert bracelet or carrying a card that notes the medication is a genuinely practical precaution for emergency scenarios where you cannot communicate.

Interactions With Alcohol and the Brain’s Reward System

Naltrexone’s interaction with alcohol is not a dangerous clash but a therapeutic one, and it works through an indirect mechanism. When a person drinks, alcohol triggers a cascade that ultimately releases dopamine in the brain’s reward center, the nucleus accumbens. Animal research has shown that naltrexone blocks this dopamine surge in a dose-dependent manner without affecting serotonin levels, demonstrating that the opioid system plays an essential role in how alcohol produces its rewarding effects.⁸ In practical terms, people on naltrexone who drink often report that alcohol simply feels less rewarding, less pleasurable, and easier to stop after one or two drinks. The alcohol still has its sedative and impairing effects, but the “buzz” feels muted.

It is worth noting that naltrexone does not make alcohol dangerous or cause a physical reaction the way disulfiram (Antabuse) does. With disulfiram, drinking triggers violent nausea and flushing because the drug blocks alcohol metabolism. Naltrexone works on the brain’s reward response instead, so there is no physical sickness from having a drink. That said, the two medications have been combined in patients with alcohol dependence and co-occurring PTSD, and the combination was found to be both effective and safe in that population.⁹

Combining Naltrexone With Antidepressants

Because alcohol use disorder and depression so frequently overlap, naltrexone is often prescribed alongside antidepressant medications. The evidence on these combinations is mixed, and the outcomes seem to depend on which antidepressant is involved.

A double-blind trial combining sertraline and naltrexone in patients with both depression and alcohol dependence found a trend toward better mood outcomes with the combination. Roughly 83% of patients in the combined medication group were no longer depressed by the end of treatment, compared to lower rates in groups receiving only one or neither drug.¹⁰ However, a separate trial combining citalopram with naltrexone in a similar population found no meaningful advantage: both mood and drinking improved in both groups, and adding citalopram to naltrexone did not produce any measurable benefit.¹¹

These results do not mean that SSRIs and naltrexone are harmful together. The concern is less about a pharmacological clash and more about whether the combination adds therapeutic value. For patients who need both an antidepressant and naltrexone, the available evidence does not suggest the two interfere with each other’s safety profiles. Your prescriber can generally combine them without expecting an adverse drug-drug interaction.

Naltrexone and Ketamine

One interaction that has drawn recent attention involves ketamine, which is increasingly used for treatment-resistant depression and is available in the nasal-spray form esketamine (Spravato). Because ketamine’s antidepressant effects appear to involve the opioid system in some way, researchers have investigated whether naltrexone pretreatment might block those effects. A case series examining combined naltrexone and ketamine in patients with depression and alcohol use disorder explored this question, though the evidence remains preliminary.¹² If you are on naltrexone and considering ketamine treatment for depression, this is a conversation worth having with your provider, because the opioid receptor blockade could theoretically blunt some of the antidepressant benefit.

Effects on Stress Hormones

Naltrexone does not just interact with other drugs. It interacts with your body’s hormonal systems, particularly the stress-response axis. By blocking opioid receptors in the brain, naltrexone disinhibits the hypothalamic-pituitary-adrenal (HPA) axis, which is the hormonal pathway that controls cortisol production. The result is a measurable rise in cortisol, the body’s primary stress hormone.¹³

In alcohol-dependent patients, naltrexone treatment produced higher levels of both ACTH (the brain hormone that signals the adrenal glands) and cortisol compared to placebo. Interestingly, higher cortisol levels correlated with lower alcohol cravings, suggesting the HPA axis activation may actually be part of how naltrexone works therapeutically.¹⁴

This hormonal interaction shows a notable sex difference. In a study of smokers given naltrexone, women showed significant increases in both ACTH and cortisol that men did not. Women estimated to be in a high-estrogen phase of their menstrual cycle had an even larger cortisol response.¹⁵ Smoking a cigarette amplified the naltrexone-induced cortisol rise in everyone. For women on naltrexone, this means the medication may produce more noticeable stress-hormone fluctuations, which could manifest as feeling jittery or anxious, particularly during certain times of the menstrual cycle.

The Naltrexone-Bupropion Combination for Weight

One of the more commercially successful naltrexone interactions is its combination with bupropion, marketed as Contrave for weight management. These two medications were not designed to work together, but researchers discovered that they produce a synergistic effect on appetite. Bupropion stimulates certain neurons in the hypothalamus that help regulate hunger, while naltrexone blocks a feedback loop that normally shuts those neurons down. The result is sustained appetite suppression that neither drug achieves well on its own.

Brain imaging research found that after treatment with the combination, subjects showed reduced hypothalamic activation in response to food cues, suggesting the drugs alter how the brain responds to the sight and smell of food at a fundamental level.¹⁶ If you are already taking bupropion for depression or smoking cessation and are prescribed naltrexone for alcohol use disorder, this appetite-suppressing effect may be something you notice. It is generally not dangerous, but significant appetite loss or weight change should be reported to your doctor.

Liver Safety at Different Doses

Naltrexone’s FDA labeling carries a warning about potential liver damage, and this is one of the interactions many patients worry about, particularly if they also drink or take other medications that stress the liver. The warning traces back to early research using very high doses (300 mg per day), which did produce meaningful rises in liver enzyme levels. However, at approved doses (50 mg oral, or the monthly injection), clinical concern about liver toxicity has not been borne out by robust evidence.

A controlled trial specifically examined liver function in patients receiving doses much higher than standard, up to 400 mg per day, for eating disorders. The study found no adverse clinical or laboratory changes in liver function even at these elevated doses.¹⁷ That said, the standard clinical practice is still to check liver enzymes before starting naltrexone and periodically during treatment. If you take naltrexone alongside other hepatically metabolized drugs or consume alcohol regularly, your provider will likely monitor more closely, though the drug itself does not appear to be the liver hazard early research feared.

Low-Dose Naltrexone and Its Interaction Profile

Low-dose naltrexone (LDN), typically in the range of 1 to 5 mg rather than the standard 50 mg, has become increasingly popular as an off-label treatment for chronic pain, autoimmune conditions, and other inflammatory states. At these low doses, naltrexone briefly blocks opioid receptors and then clears, which appears to trigger a rebound upregulation of the body’s own endorphin system and may modulate immune function by acting on receptors on immune cells.¹⁸

When it comes to drug interactions, LDN is something of a black box. A review of LDN research noted that there are no published reports of LDN interactions with other medications, but stressed that sample sizes in all existing studies have been very small, and many potential interactions simply have not been tested.¹⁹ From a pharmacological standpoint, there is little reason to expect major interactions at such low doses, though the obvious exception remains opioid painkillers. Even at low doses, naltrexone can interfere with opioid analgesia, and patients taking LDN for fibromyalgia or Crohn’s disease who are also on opioid-based pain medication face a real conflict between the two treatments.

A small proof-of-concept trial examined low-dose naltrexone as an add-on for patients with major depression who were already taking antidepressants and still symptomatic. Depression scores dropped more in the LDN group than in the placebo group across multiple rating scales, with a large effect size on some measures, though the difference did not reach statistical significance on the primary outcome.²⁰ The trial was too small to draw firm conclusions, but the signal was encouraging enough to suggest that LDN does not obviously interfere with standard antidepressant therapy and may even complement it.

Genetics and How They Shape Naltrexone’s Interactions

Not everyone responds to naltrexone the same way, and genetics are a significant reason. The most studied genetic factor is a variation in the mu-opioid receptor gene called OPRM1 A118G. A meta-analysis found that naltrexone-treated patients carrying the G version of this gene had roughly double the odds of avoiding relapse to heavy drinking compared to patients who carried only the A version.²¹ The G allele is thought to alter how the mu-opioid receptor responds to both endorphins and alcohol, potentially making naltrexone’s blockade more clinically meaningful in these individuals.

The picture gets more complex when you layer in other genes. A clinical trial found that naltrexone’s effectiveness depended on combinations of opioid and dopamine genes. Patients who carried the OPRM1 G allele alongside certain dopamine transporter or COMT genotypes showed the largest reductions in heavy drinking days on naltrexone, with moderate to large effect sizes.²² However, this finding has not been uniform across studies. A trial in patients with co-occurring depression and alcohol dependence failed to replicate the OPRM1 advantage, raising the possibility that depression alters how genetics shape naltrexone response.²³

Pharmacogenetic testing for OPRM1 status is commercially available but not yet standard clinical practice. If you have tried naltrexone without success, genetic variation is one possible explanation, though it is only one variable among many.

The Overdose Risk After Stopping Naltrexone

One of the most serious “interactions” involving naltrexone is actually what happens after you stop taking it. Prolonged opioid receptor blockade causes the brain to compensate by producing more mu-opioid receptors, a process called upregulation. Once naltrexone clears the system, those extra receptors are suddenly unblocked, making the person far more sensitive to opioids than they were before treatment began. Patients who discontinue naltrexone and relapse to opioid use face a heightened risk of fatal and nonfatal overdose because their usual dose is now dangerously potent for their newly sensitized brain.²⁴

This risk window is real and well-documented. Anyone stopping naltrexone, whether oral or injectable, should be explicitly warned that their previous opioid tolerance is gone and then some. The risk is highest in the weeks immediately following discontinuation, when receptor upregulation is at its peak but the protective blockade has waned.

Oral Versus Injectable Forms and Adherence Differences

The formulation of naltrexone you take affects how these interactions play out in practice. Oral naltrexone requires daily adherence, and a randomized trial comparing oral to extended-release injectable naltrexone in hospitalized patients with alcohol use disorder found that only about 27% of oral naltrexone patients maintained high adherence, compared to roughly 41% in the injectable group. The injectable group had about 1.9 times the odds of staying adherent.²⁵ Both groups reduced their heavy drinking days substantially, with the injectable group trending toward a greater reduction, though the between-group difference was not statistically significant.

From an interaction standpoint, the injectable form makes the opioid interaction much harder to work around. If you take oral naltrexone and face an emergency surgery, stopping the pill for a few days allows levels to fall. With the injectable form, you may have weeks of active drug in your system that cannot be removed. This is a trade-off: better adherence and relapse prevention on one side, reduced flexibility for pain management on the other.

Naltrexone During Pregnancy

Pregnant women with opioid use disorder represent a population where naltrexone’s interactions take on extra weight. Although data remain limited, a retrospective study found that babies born to mothers on naltrexone had lower rates of neonatal abstinence syndrome (about 7.5%) compared to those exposed to methadone (roughly 51.5%) or buprenorphine (about 41.8%), and spent less time in the hospital after birth.²⁶ However, compared to unexposed newborns, naltrexone-exposed babies were somewhat smaller and did have slightly elevated, though still low, rates of neonatal abstinence syndrome.

Animal studies have raised more concern, showing developmental changes in offspring exposed to naltrexone during pregnancy and lactation.²⁷ The available human data look more reassuring than the animal findings, but the sample sizes are small and the long-term effects on children are unknown. Naltrexone is not yet a first-line treatment in pregnancy, and the decision to use it involves weighing incomplete evidence in a situation where the alternative, continued opioid use, carries its own serious risks.